39 results about "Antibody formation" patented technology

The invention provides an immunoassay method based on instant synthesis of a nano-enzyme of a bimetallic CuCo Prussian blue analogue (CuCo PBA), and belongs to the field of chemical and biological sensing. According to the method, a sandwich type immune mode is formed by a glucose oxidase labeled antibody, a target object and an immobilized antibody, so that the concentration of the target object is in direct proportion to the amount of glucose oxidase. Hydrogen peroxide generated by catalyzing glucose by glucose oxidase catalyzes 3, 3 ', 5, 5'-tetramethyl benzidine (TMB) to oxidize and develop color under the assistance of CuCo PBA nano-enzyme (Cu < 2 + > and K3 [Co (CN) 6]) which is generated instantly (Cu < 2 + > and K3 [Co (CN) 6] are added instantly). And the color change of the detection liquid is recorded and is used for visual detection and quantitative detection by a microplate reader. The problems of advanced synthesis and storage of nano materials are avoided, the cost is low, the colorimetric detection method is simple in operation process, rapid in color development and high in sensitivity, and a novel method which is convenient and stable in performance is provided for clinical immunological detection.

The invention discloses a plasma or serum exosome separation method which comprises the following steps: firstly, coupling an antibody for resisting four transmembrane protein CD81 on the surface of an exosome by using a magnetic bead to form an immunomagnetic bead; pretreating a serum / plasma sample, enriching exosomes, co-incubating with the immunomagnetic beads, washing the magnetic beads after incubation capture is completed, and washing off uncombined impurities; after being captured, the exosome can be directly cracked, the magnetic beads are removed for downstream experiments, or the magnetic beads are eluted to obtain the complete exosome. The exosome affinity antibody is matched with the magnetic beads, the plasma / serum sample exosome is separated, the unique affinity separation technology not only can remove high-abundance protein in the serum / plasma sample, but also can eliminate other vesicles with similar membrane structures with the exosome, so that the purity of the separated exosome is far higher than that of the exosome obtained by other separation methods.

The present invention relates to the technical field of in-vitro testing, and in particular to a method for using a sandwich method to test a target molecule in a sample. The present invention provides a method for testing a target molecule in a sample under test, and testing is mainly performed by mean of a sandwich method, greatly improving the accuracy of testing of small molecules in serum. According to the method in the present invention, a complex-specific antibody specifically binding to a target molecule-target molecule binding protein is utilized to form a target molecule-target molecule binding protein-antibody ternary complex for testing. When a blood / serum sample containing the target molecule-target molecule binding protein is tested, in the method in the present invention, firstly, a specific dissociation solution is utilized to treat the sample under test so as to dissociate the target molecule from the target molecule-target molecule binding protein complex in the sample under test, so that the accuracy of testing of the target molecule can be further improved.

Antibodies and other molecules including an antigen binding region of an antibody that immunospecifically binds to a surface unit or a transmembrane unit of a Human endogenous retrovirus-K (HERV-K) Env protein are provided. The antibodies and other molecules typically include six complementarity determining regions (CDRs). In preferred forms the antibodies and other molecules immunospecifically bind to the amino acid sequence SEQ ID NO:223 and / or 224. Chimeric antigen receptors (CAR) formed using the provided antibodies are also provided, as are cell expressing the CAR. Methods of detecting HERV-K Env, and use thereof of various other methods such as diagnostic methods are also provided. Method of treatment for HERV-K Env protein-related diseases and disorders are also provided.

The invention discloses a biomolecule interaction detection system and method based on optical weak measurement and a double-antibody sandwich structure. High-sensitivity label-free detection is realized by integrating an optical weak value amplification technology and immune sandwich analysis. The system comprises a light source module, a polarization regulation and control module, a sensor module, an imaging module and a data processing module. The surface of a prism of the sensor module is fixedly coated with an antibody, interface refractive index change is triggered by forming a sandwich structure with an antigen and a detection antibody, and the interface refractive index change is converted into a light intensity signal through a weak value amplification effect and is captured in real time. The system eliminates environmental interference by utilizing differential signal processing, verifies data stability in combination with multiple independent experiments, has a detection limit of 6.29 ng / mL (AFP), has strong specificity and supports synchronous detection of AFP, CEA and CA15-3 multiple markers. The method does not need to mark molecules, has the advantages of high sensitivity, high flux and low cost, and provides an efficient solution for early screening of cancers.

The present technology includes methods for detecting an anti-drug antibody (ADA) that binds an anti-TNFα antibody (target antibody) in a sample comprising incubating the sample with a composition comprising an affinity antibody and a detection antibody, and isolating and detecting the ADAs that form a complex with the affinity antibody and the detection antibody. The technology also includes methods for determining the ADA concentration in a sample and confirming that a sample comprises ADAs. The technology also includes a kit for performing any of the methods of the present technology.

The invention provides a UBC-CK8 / 18 detection kit based on chemiluminescence, and the kit is characterized in that an antibody is immobilized through a streptavidin-biotin system to form a magnetic bead-biotinylated antibody-antigen-acridinium ester labeled antibody compound; after washing, the substrate solution excites the acridinium ester to generate a photon signal, and a relative luminescence unit (RLUs) is captured by a full-automatic chemiluminescence immunoassay instrument, so that rapid and low-cost clinical detection of bladder cancer is realized, and the detection performance is good.

Provided (Ia) are conjugator-functionalized pyrrolobenzodiazepine (PBD) dimer compounds of Formula (I), wherein structures A and B are PBDs and conjugator is a group capable of forming a covalent linkage with an antibody. Also disclosed are antibody-drug conjugates comprising the conjugator-functionalized PBD dimer compounds.

The invention discloses a tumor necrosis factor alpha detection kit using a chemiluminescence immunoassay technology, and relates to the technical field of detection kits. An anti-human tumor necrosis factor alpha antibody is used for coating a microporous ELISA plate, after a standard substance is added, the tumor necrosis factor alpha can be tightly combined with the coating antibody, then a detection antibody is added to form a stable antibody-antigen-enzyme-labeled antibody compound, free components are thoroughly removed through plate washing operation, then a chromogenic substrate TMB is added, and the detection sensitivity is high. The TMB is blue under the catalysis of a detection antibody, finally, the TMB is converted into yellow after a stop buffer is added, the depth of the color is positively correlated with the concentration of the tumor necrosis factor alpha in a sample, the absorbance is measured through an enzyme-linked immunosorbent assay instrument, the concentration of the sample can be accurately calculated, and the fixed seat can be prevented from shifting under the cooperation of a connecting shaft and a roller; and by arranging the bearing mechanism, the purposes of stretching out and storing the fixing mechanism can be achieved, and taking, placing and protection are facilitated.

The invention belongs to the technical field of bioengineering, and particularly relates to an in-vitro immunodetection method based on an optically-excited electrically-driven active oxygen channel. The method provided by the invention is used for detecting the target protein in a biological sample, and comprises the following steps: preparing a donor bead compound containing a photosensitizer and a receptor bead compound containing polyphenol, putting the donor bead compound and the receptor bead compound into a biological sample solution to be detected, and when the biological sample to be detected contains the target protein, detecting the target protein in the biological sample to be detected. The target protein recognizes and is combined with the capture antibody and the detection antibody to form a sandwich immune structure, and a donor bead-acceptor bead connector of the target protein is obtained for detection. The method is accurate in detection result and high in sensitivity.

The present invention relates to a method for forming a multispecific antibody from a first and a second homodimeric antibody, comprising the steps of:-providing at least one solution comprising said homodimeric antibody; -loading said at least one solution onto an adsorption chromatography medium such that said homodimer antibody binds to said medium; contacting the bound antibody with a reducing agent; and-eluting the bound antibodies with an elution buffer, thereby obtaining an eluate pool. The method further comprises a step of contacting the bound or eluted antibody with an oxidizing agent after the step of contacting the bound antibody with the reducing agent, thereby forming a multispecific antibody from the first and second homodimeric antibodies. The invention also relates to a pharmaceutical product comprising a multispecific antibody obtained by such a method.

The invention provides a photoluminescence molecule enhanced metasurface plasma resonance sensor and a preparation method thereof, and belongs to the technical field of metasurface plasma resonance sensors. Based on the photo-crosslinking polysaccharide sensor, a double-antibody sandwich detection system is formed through the antibody marked by photoluminescence molecules, the signal intensity and specificity of the metasurface plasma resonance sensor are remarkably enhanced, and target protein with lower concentration can be detected. The sensor disclosed by the invention has wide application potential, and is suitable for early diagnosis and monitoring of various diseases, especially occasions requiring high sensitivity and specificity; in addition, according to the sensor, the traditional signal amplification step is simplified, and the sensor has the advantages of being easy to operate and low in cost.

This invention relates to crystals of the human Gremlin-1 protein, and the human Gremlin-1 protein in complex with an inhibitory antibody. The invention also relates to the structure of human Gremlin-1 (on its own, or in complex with the antibody) and uses of these structures in screening for agents which modulate Gremlin-1 activity. The invention further provides antibodies which bind an allosteric inhibitory site on Gremlin-1, together with pharmaceutical compositions and medical uses of such antibodies and agents identified by the screening methods.

The invention provides an IgG (immunoglobulin G) binding type immune activator protein as well as a preparation method and application thereof, and belongs to the technical field of medicines. It is found for the first time that after three Fab binding peptides CFab and N215 are fused, the N215 can be endowed with the IgG antibody binding capacity, the obtained fusion protein N215-CFab3 and the IgG antibody can form a stable compound, and the compound retains the functions of the N215 and the antibody, can mediate binding of the N215 to target cells, remarkably prolongs the half-life period of the N215, promotes proliferation of T and NK cells, and has the advantages of being capable of achieving the purpose of improving the immunogenicity of the N215 and improving the immunogenicity of the N215. The remarkably enhanced in-vivo anti-tumor effect is exerted. A compound formed by the fusion protein N215-CFab3 and an IgG antibody can be used as an immune activator, and has a wide application prospect in immunotherapy of diseases such as tumors and infection.

The invention belongs to the technical field of immunological detection, and particularly discloses a monoclonal antibody resisting human monocyte chemoattractant protein 1, a kit containing the monoclonal antibody and application of the monoclonal antibody. The monoclonal antibody is a paired antibody, comprises a 6H11 antibody and a 1F12 antibody, and can specifically recognize human monocyte chemotactic protein 1. A human MCP-1 antibody (6H11) is coated with an elisa plate to form a solid-phase carrier, the solid-phase carrier is combined with an MCP-1 antigen in a biological sample to be detected, an antibody (1F12) is detected through specific enzyme labeling, a solid-phase antibody-antigen-enzyme labeled antibody compound is formed, and detection is performed through intervention of a chromogenic substrate solution. The detection kit provided by the invention adopts a one-step method, a standard product / sample and an enzyme-labeled antibody are added together for reaction during detection, the reaction time does not exceed 1h, the whole experimental operation steps are few, the time is short, the sensitivity is high, and the precision and the accuracy are good.

This invention belongs to the field of CT imaging technology and relates to a bismuth-based imaging contrast agent and its preparation method. The bismuth-based imaging contrast agent is formed by chelating bismuth ions with DTPA modified with aminosulfonic acid, followed by surface-linking with an antibody. The preparation method includes: a first reaction of DTPA and aminosulfonic acid in the presence of an activator to obtain aminosulfonic acid-modified DTPA; a second reaction of DTPA with an inorganic bismuth salt in a second solvent, followed by pH adjustment to neutral and drying to obtain aminosulfonic acid-modified DTPA chelated with bismuth ions; and a third reaction of the aminosulfonic acid-modified DTPA chelated with bismuth ions with an antibody, followed by drying. The CT imaging contrast agent exhibits excellent CT imaging capabilities, high safety, and tumor cell killing ability.

The present invention discloses an antibody combination for detecting mycobacterial lipoarabinomannan, its application, and a kit, relating to the field of biological detection. The inventors of this application screened and identified various sample types, identifying capture antibodies suitable for LAM antigen capture and detection antibodies suitable for LAM antigen detection. This resulted in a superior antibody combination for LAM antigen detection, which exhibits high sensitivity and specificity and can be used to detect LAM antigens in purified LAM, standard strains of Mycobacterium tuberculosis, clinical isolates, pleural effusions, plasma, and other bodily fluids. This provides a new antibody combination and method for LAM antigen detection, as well as a new method and kit for the auxiliary diagnosis of active tuberculosis.

The present application relates to a kind of based on electrochemiluminescence immunoassay semeglu-tide content detection method, the kit for detecting semeglu-tide and monoclonal antibody pair, it solves the technical problem that the prior art through LC-MS / MS determination semeglu-tide content exists and is complex, detection flux is low, impurity residue, sample loss amount is big and traditional ELISA detection sensitivity is low, it is by the way that one monoclonal antibody reagent AS-MAB01 is coated on electrochemiluminescence microplate, specifically recognizes and combines semeglu-tide in matrix, then another monoclonal antibody AS-MAB02 labeled with ruthenium is added to form sandwich complex, finally, high sensitivity semeglu-tide quantitative detection purpose is achieved by electrochemiluminescence principle.The present application can be used for the quantitative detection of semeglu-tide in mouse, monkey and human-derived serum samples.

The invention relates to a semeglutide content detection method based on electrochemical luminescence immunoassay, a kit for detecting semeglutide and a monoclonal antibody pair. The technical problems that in the prior art, when the content of the semeglutide is measured through LC-MS / MS, pretreatment is complex, the detection flux is low, impurity residues exist, the sample loss amount is large, and traditional ELISA detection sensitivity is low are solved. The method comprises the following steps of: specifically identifying and combining the semeglutide in a matrix, then adding another ruthenium-labeled monoclonal detection antibody AS-MAB02 to form a sandwich compound, and finally achieving the purpose of high-sensitivity semeglutide quantitative detection through an electrochemical luminescence principle. The method can be used for quantitative detection of the semeglutide in serum samples of mouse, monkey and human sources.

The embodiment of the invention provides a PLGF and sFlt-1 double-marker joint detection kit and application. The kit comprises an sFlt-1 labeled antibody, a PlGF labeled antibody, an antibody coated fluorescent magnetic bead working solution, an antibody calibrator, a sample diluent, a cleaning solution, an enzyme solution and an enzyme substrate solution. According to the application, specific capture antibodies of sFlt-1 and PlGF are respectively coupled to different fluorescence coded magnetic beads, so that the specific capture antibodies, an antigen and a detection antibody form a double-antibody sandwich structure, and the double-antibody sandwich structure is cleaned, uniformly mixed and synchronously imaged, so that synchronous and simultaneous testing of sFlt-1 and PlGF in the same sample is realized, and high-resolution quantitative analysis is carried out. Therefore, the application of the joint detection kit significantly simplifies the detection process, reduces the cost, improves the detection flux and efficiency, effectively improves the sensitivity and accuracy of preeclampsia risk assessment, and has important clinical popularization value.

Provided herein are tetravalent antibodies and immunoconjugates in which the antibodies are conjugated with a payload. The antibodies can comprise a number of different architectures in which paratopes, formed as, for example, Fabs or diabodies, are positioned relative to each other and to an Fc region. Methods of making and using the aforementioned antibodies and immunoconjugates are also provided.

The present application provides a novel coronavirus antibody detection kit based on magnetic particle chemiluminescence. The detection kit includes: streptavidin magnetic particles, biotin-labeled novel coronavirus antigens, an acridine sulfonamide-labeled secondary antibody, a sample diluent and a quality control material; wherein the biotin-labeled novel coronavirus antigens include a recombinant nucleocapsid protein and a recombinant spike protein S1. The sample to be tested, the biotin-labeled antigens and the streptavidin magnetic particles are mixed, incubated and washed, and then the acridine sulfonamide-labeled antibody is added to form a magnetic particle-streptavidin-biotin-antigen-novel coronavirus antibody-secondary antibody complex, and then the luminous intensity is detected to qualitatively determine the sample to be tested.

The invention discloses a kappa light chain detection kit and a preparation method, and relates to the technical field of clinical in-vitro detection reagents, the kit is in a double-reagent form, the double reagents comprise a reagent R1 and a reagent R2, the reagent R2 comprises a capture antibody and a detection antibody which can be specifically combined with different epitopes of a kappa light chain, and the detection antibody comprises a reagent R1 and a reagent R2 which can be specifically combined with different epitopes of the kappa light chain. A capture antibody-antigen-detection antibody sandwich structure is formed to improve the hook effect in detection. The kappa light chain detection reagent provided by the invention solves the problems that the existing kappa light chain detection reagent mostly uses a single antibody and a hook effect is easy to occur due to reduction of a HOOK point, a capture antibody-antigen-detection antibody sandwich structure is formed by two antibodies (capture antibody and detection antibody) aiming at different epitopes of an antigen, and the core is a specific binding mode, so that the recognition precision of the antigen can be improved, and the detection accuracy of the kappa light chain detection reagent is improved. And non-specific binding is reduced, the detection sensitivity and HOOK point are greatly improved, and further popularization and application in the market are facilitated.

The invention aims at providing an acute gouty arthritis diagnosis and treatment preparation based on natural antioxidants and a preparation method and application thereof, and belongs to the technical field of nano biomedical materials.The acute gouty arthritis diagnosis and treatment preparation is self-assembled with spheroidic tea polyphenol and acidified rutin as sources and comprises a polyphenol hydroxyl structure of the natural antioxidants, and the natural antioxidants are added into the polyphenol hydroxyl structure of the natural antioxidants; the nano-probe is formed by coating maleoyl bovine serum albumin (MBSA) and then coupling a NOX2 antibody through an antibody drug coupling technology, and the nano-probe with integrated diagnosis and treatment of acute gouty arthritis is constructed. The nano probe can be used for positioning an acute gouty arthritis part in real time under the guidance of near-infrared region imaging; the probe can directionally remove macrophages and microenvironment high-expression reactive oxygen species (ROS), and the preparation method of the probe is simple and easy to implement.

This invention discloses a long-chain carboxyl microsphere, its preparation method, and a kit. The conventional method for preparing polystyrene (PS) carboxyl microspheres is improved by using long-chain carboxyl functional monomers such as 3-methyl-4-pentenoic acid and 5-methyl-5-hexenoic acid, which have similar structures. Using these functional monomers to prepare microspheres promotes longer carboxyl chains, overcoming steric hindrance. Crosslinking the prepared microspheres with amino-containing small-molecule haptens allows for turbidity reactions with corresponding antibodies, eliminating the need for pre-crosslinking of small-molecule antigens with proteins. A kit constructed using the conjugated small-molecule microspheres exhibits satisfactory calibration curves and can be used to detect the content of corresponding substances in samples.

The invention discloses a novel immunodetection method and application. The immunodetection method comprises the following steps: coating a captured antibody and a single-site recognition antigen on a solid-phase carrier; adding a to-be-detected sample and a biotin-labeled mixed detection antibody for incubation, so that the target antigen forms a double-antibody sandwich compound, and the single-site recognition antigen and the detection antibody form a competitive compound; after streptavidin marked by chemiluminescence is added for incubation, signal values of the two compounds are detected; whether interference exists or not is judged and detected by comparing the double signals, and the content of the target antigen is determined. The immunodetection method can effectively identify cross interference and hook effect, and improves the accuracy and reliability of multi-index detection.

The present technology includes a method for detecting anti-drug antibodies (ADAs) that bind to anti-TNF [alpha] antibodies (target antibodies) in a sample, the method comprising incubating the sample with a composition comprising an affinity antibody and a detection antibody, and isolating and detecting the ADAs that form complexes with the affinity antibody and the detection antibody. The techniques also include methods for determining the concentration of ADA in a sample and confirming that the sample contains ADA. The technology also includes a kit for performing any of the methods of the technology.

The invention relates to the technical field of biological detection, and provides a visual allergy-infection duplex detection device based on a partitioned nanofiber membrane. According to the device, a functional nanofiber membrane is integrally constructed through an electrostatic spinning technology, hydrophilic PVA nanofibers are taken as a substrate, bifunctional integration is realized through precise partition design in combination with immunochromatography and a color development mechanism, an allergy detection region adopts PVA nanofibers to encapsulate an anti-human ECP capture antibody and a colloidal gold-anti-ECP detection antibody, and the sensitivity of the detection region is greatly improved. An antibody-antigen compound is formed to capture ECP in saliva and display a red signal; the infection detection area adopts gelatin and PLGA (poly (lactic-co-glycolic acid)) nanofiber to encapsulate Fe3O4 nano enzyme and 3, 3 ', 5, 5'-tetramethyl benzidine. The detection nanofiber membrane provided by the invention has the capability of joint detection of allergy and infection, good detection efficiency and long-term stability, can realize dynamic monitoring of the allergy state and infection risk of a COPD patient through a non-invasive saliva sample, and provides indication for prognosis management of the COPD patient.

This invention relates to a protein detection method. Specifically, the method introduces magnetic beads to capture antibodies that bind to the target protein structure, forming a triple-antibody sandwich protein-magnetic bead complex. This complex is then detected to obtain the target protein detection result. The method of this invention exhibits good stability, high sensitivity, high efficiency, low background signal, and simple operation steps.

The present invention provides a composition comprising the following thyroid stimulating hormone receptor (TSHR) peptides: (i) all or a portion of the amino acid sequence KKKKYVSIDVTLQQLESHKKK (SEQ ID NO: 1), or a portion thereof, or a sequence having at least 60% sequence identity to SEQ ID NO: 1; and (ii) all or a portion of the amino acid sequence GLKMFPDLTKVYSTD (SEQ ID NO: 2), or a portion thereof, or a sequence having at least 60% sequence identity to SEQ ID NO: 2. The invention also relates to the use of such compositions in the prevention or inhibition of activated autoantibody formation in Graves's disease.